Durvalumab with enfortumab vedotin for neoadjuvant and adjuvant treatment of muscle-invasive bladder cancer when cisplatin is unsuitable [ID6445]

  • Awaiting development
  • GID-TA11517
  • Expected publication date: TBC

33623-Durvalumab-Enfortumab-Vedotin-or-Tremelimumab-for-Muscle-Invasive-Bladder-Cancer-V1.0-JAN2024-NON-CONF.pdf (nihr.ac.uk)